A Real-World Pharmacovigilance Analysis of Lorlatinib-Associated Metabolic Effects Using the FDA Adverse Events Reporting System (FAERS) Database From 2013 to 2024
These findings highlight the need for proactive monitoring and management of metabolic side effects in patients receiving lorlatinib. A multidisciplinary approach-incorporating pharmacologic interventions, lifestyle modifications, and regular monitoring-is essential to mitigate metabolic risks. This study enhances the understanding of lorlatinib's safety profile and informs clinical strategies to balance efficacy and tolerability in ALK inhibitor therapy.
Authors
- Connor Frey (ORCID: https://orcid.org/0000-0002-4080-3030)
Institutions
- University of British Columbia (CA)
Publication Details
- Journal
- Endocrine Practice
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1016/j.eprac.2025.03.016
- Citations
- 2
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 2.61